| __timestamp | Halozyme Therapeutics, Inc. | MannKind Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 35942000 | 79383000 |
| Thursday, January 1, 2015 | 40028000 | 108402000 |
| Friday, January 1, 2016 | 45853000 | 46928000 |
| Sunday, January 1, 2017 | 53816000 | 74959000 |
| Monday, January 1, 2018 | 60804000 | 79716000 |
| Tuesday, January 1, 2019 | 77252000 | 74669000 |
| Wednesday, January 1, 2020 | 45736000 | 59040000 |
| Friday, January 1, 2021 | 50323000 | 77417000 |
| Saturday, January 1, 2022 | 143526000 | 91473000 |
| Sunday, January 1, 2023 | 149182000 | 94314000 |
| Monday, January 1, 2024 | 154335000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. From 2014 to 2023, Halozyme Therapeutics, Inc. and MannKind Corporation have shown distinct strategies in optimizing these costs. Halozyme's SG&A expenses have seen a significant increase, peaking at nearly 150% of their 2014 levels by 2023. This suggests a strategic investment in administrative capabilities, possibly to support growth initiatives. In contrast, MannKind's expenses have remained relatively stable, with a modest increase of about 19% over the same period. This stability might indicate a focus on maintaining lean operations. The data highlights how each company navigates the balance between cost management and strategic investment, offering valuable insights into their operational priorities.
Comparing SG&A Expenses: Zoetis Inc. vs MannKind Corporation Trends and Insights
SG&A Efficiency Analysis: Comparing Viatris Inc. and Halozyme Therapeutics, Inc.
Halozyme Therapeutics, Inc. and Apellis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Halozyme Therapeutics, Inc. or ADMA Biologics, Inc.: Who Manages SG&A Costs Better?
Halozyme Therapeutics, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs Bausch Health Companies Inc.
Comparing Innovation Spending: Halozyme Therapeutics, Inc. and MannKind Corporation
SG&A Efficiency Analysis: Comparing Axsome Therapeutics, Inc. and MannKind Corporation
Cost Management Insights: SG&A Expenses for CymaBay Therapeutics, Inc. and MannKind Corporation
Comparing SG&A Expenses: Viking Therapeutics, Inc. vs MannKind Corporation Trends and Insights
MannKind Corporation and Celldex Therapeutics, Inc.: SG&A Spending Patterns Compared
MannKind Corporation and Dynavax Technologies Corporation: SG&A Spending Patterns Compared